MRR. 25. 2005 9:18AM TTC-PA 650-326

NO.349 P. 4 CENTRAL FAX CENTER

MAR 2 5 2005

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

2005.

TOWNSEND and TOWNSEND and CREW LLP

Attorney Docket No.: 15270J-4729US Client Ref. No.: 209-US-CIP4C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF

AMYLOIDOGENIC DISBASB

Examiner:

Laurie Scheiner

Art Unit:

1648

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

- 1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
- Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")

PAGE 416 * RCVD AT 3725/2005 12:11:35 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-410 * DHIS:8729306 * CSED:16503262422 * DURATION (min-ss):01-52

MAR. 25. 2005 9:000M TTC-PA 650-326-2422

CENTRAL FAX CENTER

NO.343

MAR 2 5 2005

Pheroby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Pax. No. 1-703-872-9306 on

2005.

TOWNSEND and TOWNSEND and CREW LLP

Attorney Docket No.: 15270J-4729US

Client Ref. No.: 209-US-CIP4C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF

AMYLOIDOGENIC DISEASE

Examiner:

Laurie Scheiner

Art Unit:

1648

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter. "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

- 1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
- Application No. 09/724,102 Issued as U.S. Patent No. 6,787,139 (the "139 PATENT")

PAGE 416 * RCVD AT 3/25/2005 11:54:05 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-U1 * DNIS:8729305 * CSID:16503262422 * DURATION (mm-ss):02-02

03/28/2005 NVILLARI 00000010 201430 10815391

02 FC:1814

130.00 DA

MAR.25.2005 8:57AM

TTC-PA 650-326-2422

RECEIVED
CENTRAL FAX CENTER

NO.342 P.4/6

MAR 2 5 2005

1 hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

25 2005

TOWNSEND and TOWNSEND and CREW LLP

By Aut Ru

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF

AMYLOIDOGENIC DISRASE

Examiner:

Laurie Scheiner

Attorney Docket No.: 15270J-4729US

Client Ref. No.: 209-US-CIP4C4.

Art Unit:

1648

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

- 1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
- 2. Application No. 09/724,489 Issued as U.S. Patent No. 6,787,140 (the "140 PATENT")

PAGE 4/6 * RCVD AT 3/25/2005 11:51:09 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/0 * DNIS:8729305 * CSID:16503262422 * DURATION (mm-ss):01-48

MAR. 25. 2005 TTC-PA 650-326-2422

NO.345 RECEIVED CENTRAL FAX CENTER

MAR 2 5 2005

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

Attorney Docket No.: 15270J-4729US Client Ref. No.: 209-US-CIP4C4

2005.

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF

AMYLOIDOGENIC DISEASE

Examiner:

Laurie Scheiner

Art Unit:

1648

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

- Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
- 2. Application No. 09/201,430 Issued as U.S. Patent No. 6,787,523 (the "523 PATENT")

PAGE 416 * RCVD AT 3/25/2005 12:00:04 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/0 * DHIS:8729305 * CSID:16503262422 * DURATION (mm-ss):02-02

MAR. 25. 2005 9:09AM

RECEIVED CENTRAL FAX CENTER NO.346

MAR 2 5 2005

I hereby certify that this correspondence is being factimile transmitted to the U.S. Patent and Trademark Office. Fax

No. 1-703-872-9306 on

TOWNSEND and TOWNSEND and CREW LLP

PATENT

Attorney Docket No.: 15270J-4729US Client Ref. No.: 209-US-CIP4C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF

AMYLOIDOGENIC DISRASE

Examiner:

Laurie Scheiner

Art Unit:

1648

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

- Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
- Application No. 09/723,762 Issued as U.S. Patent No. 6,787,144 (the "144 PATENT")

PAGE 4/6 * RCVD AT 3/25/2005 12:02:33 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:16503762422 * DURATION (mm-ss):02-12

MAR. 25. 2005 9: 03AM TTC-PA 650-326-2422

RECEIVED NO.344 P.4/ CENTRAL FAX CENTER

Attorney Docket No.: 15270J-4729US

MAR 2 5 2005

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Parent and Trademark Office, Fax

No. 1-703-872-9306 on

Client Ref. No.: 209-US-CIP4C4

TOWNSEND and TOWNSEND and CREW LLP

or Clubart 113pm

2005.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF

AMYLOIDOGENIC DISEASE

Examiner:

Lauric Scheiner

Art Unit:

1648

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

- Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
- 2. Application No. 09/723,927 Issued as U.S. Patent No. 6,787,138 (the "138 PATENT")

PAGE 416 * RCVD AT 3/25/2005 11:57:09 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-111 * DNIS:8729306 * CSID:16503262422 * DURATION (mm-ss):01-48

RECEIVED CENTRAL FAX CENTER

MAR 2 5 2005

I hereby certify that this correspondence is being facaimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

Norch 25 ,2005

TOWNSEND and TOWNSEND and CREW LLP

Reduced Ber

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF

AMYLOIDOGENIC DISBASE

Examiner:

Laurie Scheiner

Attorney Docket No.: 15270J-4729US

Client Ref. No.: 209-US-CIP4C4

Art Unit:

1648

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

- Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
- 2. Application No. 10/816,022 Issued as U.S. Patent No. 6,866,850 (the "850 PATENT")

PAGE 416 * RCVD AT 372\$72005 12:05:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID:16503262422 * DURATION (mm-ss):01-64

MAR. 25. 2005 TTC-PA 650-326-2422

RECEIVED CENTRAL FAX CENTER

NO.341

MAR 2 5 2005

I hereby certify that this correspondence is being facaimile transmitted to the U.S. Patent and Trademark Office, Pax No. 1-703-872-9306 cm

Attorney Docket No.: 15270J-4729US Client Ref. No.: 209-US-CIP4C4

2005.

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF

AMYLOIDOGENIC DISEASE

Examiner:

Laurie Scheiner

Art Unit:

1648

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

- Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
- Application No. 09/724,477 Issued as U.S. Patent No. 6,787,143 (the "143 PATENT")

PAGE 4/6 * RCVD AT 3/25/2005 11:47:50 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/1 * DHIS:8729303 * CSID:16503262422 * DURATION (mm-ss):02-02

03/28/2005 NVILLARI 00000005 201430 10815391

01 FC:1814

130.00 DA